Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

GlobeNewswire March 25, 2024

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 29, 2024

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

GlobeNewswire February 15, 2024

Amarin Chairman & CEO Issue Letter to Shareholders

GlobeNewswire January 22, 2024

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

GlobeNewswire January 10, 2024

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 11, 2023

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

GlobeNewswire November 12, 2023

Amarin Reports Third Quarter 2023 Financial Results

GlobeNewswire November 1, 2023

Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer

GlobeNewswire October 31, 2023

Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023

GlobeNewswire October 26, 2023

 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023

GlobeNewswire October 19, 2023

Amarin to Present at the 2023 Cantor Global Healthcare Conference

GlobeNewswire September 12, 2023

Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy

GlobeNewswire August 9, 2023

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

GlobeNewswire August 8, 2023

Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)

GlobeNewswire August 7, 2023

Amarin Reports Second Quarter 2023 Financial Results

GlobeNewswire August 2, 2023

Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea

GlobeNewswire July 31, 2023

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

GlobeNewswire July 26, 2023

Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain

GlobeNewswire July 25, 2023

Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt

GlobeNewswire July 20, 2023